Education
About Us
Working with TipRanks
Follow Us
Anika Therapeutics (ANIK)
NASDAQ:ANIK
ANIK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$14.77 - $29.12
Previous CloseN/A
Volume22.29K
Average Volume (3M)81.27K
Market Cap
$213.07M
Enterprise Value$329.94M
Total Cash (Recent Filing)$23.17M
Total Debt (Recent Filing)$14.00M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
May 07, 2025EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.84
Shares Outstanding14,175,994
10 Day Avg. Volume77,016
30 Day Avg. Volume81,266
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.33
Price to Cash Flow (P/CF)10.90
P/FCF Ratio17.10
Enterprise Value/Market Cap1.55
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.34
Enterprise Value/Ebitda227.07
Forecast
1Y Price Target
$24.00Price Target Upside59.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Anika Therapeutics News
PremiumCompany Announcements
Anika Therapeutics’ Earnings Call: Growth Amid Challenges
PremiumCompany Announcements
Anika Therapeutics Reports Steady Growth and Strategic Focus
PremiumCompany Announcements
Anika Therapeutics Sells Parcus Medical to Medacta
PremiumPre-Earnings
Is ANIK a Buy, Before Earnings?
PremiumCompany Announcements
Anika Therapeutics Navigates Geopolitical Risks Amid Global Conflicts---
Bulls Say, Bears Say
Bulls Say
EarningsAnika generated $30.6 million in revenue, exceeding both the company's estimate and the consensus estimate.
Financial StrategyAnika disclosed that it had repurchased $5.6 million of its shares, completing the initial $15 million share repurchase commitment.
Product DevelopmentNew products are expected to primarily fuel the double-digit growth in the company's Joint Preservation & Restoration business.
Bears Say
Financial PerformanceAdjusted EPS of -$0.25 fell massively short of expectations.
Pricing And Volume ChallengesThe company is facing volume and pricing headwinds in the U.S. for its OA pain management products.
Regulatory ChallengesCingal has faced regulatory delays with slow-moving conversations with the FDA.
---
Ownership Overview
3.53% Insiders
14.43% Mutual Funds
39.90% Other Institutional Investors
30.74% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ANIK FAQ
What was Anika Therapeutics’s price range in the past 12 months?
Anika Therapeutics lowest stock price was $14.77 and its highest was $29.11 in the past 12 months.
What is Anika Therapeutics’s market cap?
Anika Therapeutics’s market cap is $213.07M.
When is Anika Therapeutics’s upcoming earnings report date?
Anika Therapeutics’s upcoming earnings report date is May 07, 2025 which is in 33 days.
How were Anika Therapeutics’s earnings last quarter?
Anika Therapeutics released its earnings results on Mar 12, 2025. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.225 by $0.195.
Is Anika Therapeutics overvalued?
According to Wall Street analysts Anika Therapeutics’s price is currently Undervalued.
Does Anika Therapeutics pay dividends?
Anika Therapeutics does not currently pay dividends.
What is Anika Therapeutics’s EPS estimate?
Anika Therapeutics’s EPS estimate is -0.02.
How many shares outstanding does Anika Therapeutics have?
Anika Therapeutics has 14,175,994 shares outstanding.
What happened to Anika Therapeutics’s price movement after its last earnings report?
Anika Therapeutics reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.225. Following the earnings report the stock price went down -11.105%.
Which hedge fund is a major shareholder of Anika Therapeutics?
Currently, no hedge funds are holding shares in ANIK
---
Anika Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$24.00 (59.47% Upside)
$24.00 (59.47% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.73%
12-Months-Change
Fundamentals
Return on Equity
-20.21%
Trailing 12-Months
Asset Growth
-24.69%
Trailing 12-Months
Company Description
Anika Therapeutics
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
---
ANIK Company Deck
---
ANIK Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
While there are notable achievements such as significant growth in the commercial channel, international OA pain management, and the Integrity implant system, challenges persist with declines in the OEM channel revenue and adjusted EBITDA. The financial outlook remains cautious with profitability impacted by pricing pressures from J&J in the OEM segment and decreased gross margins.Read More>---
ANIK Stock 12 Month Forecast
Average Price Target
$24.00
▲(59.47% Upside)
Technical Analysis
Best Analysts Covering ANIK
1 Year
1 Year Success Rate
5/26 ratings generated profit
1 Year Average Return
-12.59%
reiterated a buy rating 22 days ago
Copying Michael Petusky's trades and holding each position for 1 Year would result in 19.23% of your transactions generating a profit, with an average return of -12.59% per trade.
---